How should kidney function be monitored during Ribociclib therapy?

Serum creatinine each cycle (with cystatin-C eGFR if it rises); Serum potassium, magnesium, and total/ionized calcium; ECG/QTc at baseline, ~day 14, and start of cycle 2; LFTs and CBC per label.

How can kidney injury from Ribociclib be prevented?

Confirm true GFR (cystatin C / measured GFR) before attributing a creatinine rise to nephrotoxicity Correct and monitor potassium, magnesium, and calcium before and during therapy Baseline and on-treatment ECG; avoid unnecessary QT-prolonging or nephrotoxic co-medications

Who is at higher risk of kidney injury from Ribociclib?

Older age; Elevated baseline renal indices; Concurrent QT-prolonging drugs or baseline electrolyte abnormalities; Strong CYP3A4 inhibitors increasing exposure.

Back to explorer

Printable monograph

CDK4/6 inhibitor

Ribociclib

Kisqali · Ribo

CDK4/6 inhibitor · approved 2017 · 9 citations · FAERS AKI reporting ROR 1.49 (95% CI 1.34–1.66, 339 AKI reports)

Up to date· through 2026

Fairly sourced6/9 · 6 signals

Met: 9 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 5y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2026
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

CDK4/6 inhibitor whose creatinine bump is mostly transporter inhibition, with QT prolongation to watch.

MildCDK4/6 inhibitor

HR-positive HER2-negative breast cancer

§01

Signature kidney injury

Signature lesion

Pseudo-AKI

Representative incidence14%

Like other CDK4/6 inhibitors, ribociclib produces a frequent, reversible creatinine rise via inhibition of tubular creatinine secretion (pseudo-AKI ~14% in a class-effect analysis); clinically meaningful structural AKI is uncommon. A retrospective cohort of palbociclib/ribociclib patients found a >=20% creatinine-clearance decline in about 23%.Source: Ly et al., J Oncol Pharm Pract 2026 (PMID 39648753 — source of the 14% headline: pseudo-creatinine elevation in 6/43 ribociclib patients, all grade 1-2); Avci et al., Ther Adv Med Oncol 2026 (PMID 41523909 — a different endpoint: ≥20% CrCl decline in 28/120 (23%) of a mixed palbociclib/ribociclib cohort). Most ribociclib creatinine rise is transporter-mediated pseudo-AKI, not structural injury.

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

The creatinine signal appears in the first cycles (median onset roughly 6 weeks) and reverses on hold or discontinuation, with QTc effects seen early.

Distilled from: “First cycles (median onset roughly 6 weeks for the creatinine signal); reversible on hold or discontinuation. QTc effects are dose- and concentration-dependent and seen early.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Pseudo-AKI#1 · Signatureno population incidence denominator
Class effect: predominant renal signal is pseudo-AKI (creatinine rise from OCT2/MATE inhibition without a real GFR decline); true AKI (acute tubular injury, interstitial nephritis) is rare PMID 41385991 (opens PubMed in a new tab)
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Electrolyte DisturbanceRareno population incidence denominator
Hypokalemia/hyponatremia reported but uncommon relative to the near-universal creatinine change PMID 41385991 (opens PubMed in a new tab)

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

14%incidence

SeverityMild

ReversibilityReversible

Evidence9 citations

Nephron map

Vasculature / Endothelium

Proximal TubuleBulk reabsorption + drug uptake (OCT2, OATs)

Distal Tubule / Collecting Duct

Pseudo-AKI

The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.

§03

Kidney injury

Mechanism of kidney injury

Inhibits proximal-tubular OCT2 and MATE transporters that secrete creatinine, elevating serum creatinine independent of GFR. Ribociclib additionally carries dose-dependent QTc prolongation, so co-existing hypokalemia, hypomagnesemia, and hypocalcemia must be corrected to limit torsades risk; these electrolyte disturbances are a distinct safety axis rather than a sign of tubular injury.

Clinical presentation

Early asymptomatic creatinine rise with preserved cystatin-C-based/measured GFR and bland urinalysis. Separately, monitor ECG/QTc and serum electrolytes per labeling, especially in the first cycles.

Management

Treat as pseudo-AKI when cystatin C/measured GFR is stable and sediment is bland; continue therapy. Manage QTc and electrolytes per protocol (hold/reduce if QTcF >480-500 ms). Reserve dose modification for genuine renal decline.Lesion-level management framework

Risk factors

Older age
Elevated baseline renal indices
Concurrent QT-prolonging drugs or baseline electrolyte abnormalities
Strong CYP3A4 inhibitors increasing exposure

Prevention

Confirm true GFR (cystatin C / measured GFR) before attributing a creatinine rise to nephrotoxicity
Correct and monitor potassium, magnesium, and calcium before and during therapy
Baseline and on-treatment ECG; avoid unnecessary QT-prolonging or nephrotoxic co-medications

Anticancer mechanism· how it treats cancer

Selective CDK4/6 inhibitor that halts the cell cycle at the G1/S checkpoint by preventing Rb phosphorylation; combined with endocrine therapy in HR-positive, HER2-negative advanced/metastatic breast cancer, with a demonstrated overall-survival benefit (e.g. MONALEESA-7: median OS 58.7 vs 48.0 months).

Note · Creatinine rise plus QTc prolongation; the renal signal is largely artefactual OCT2/MATE inhibition, while the electrolyte/QT axis is the clinically actionable safety concern.

§04

Clinical depth

Renal dose adjustment

No adjustment for mild-moderate renal impairment; the label provides a reduced starting dose (e.g. 200 mg) for severe impairment. Avoid strong CYP3A4 inhibitors or reduce dose accordingly.

Dialyzability & ESKD dosing

Extensively hepatically metabolized (CYP3A4), highly protein-bound; not expected to be removed by hemodialysis. No HD-timed dosing established.

Differential diagnosis

Transporter-mediated pseudo-AKI (stable cystatin C) vs prerenal azotemia vs rare true ATN/AIN. QTc prolongation with electrolyte derangement is a separate toxicity, not evidence of kidney injury.

Monitoring

Serum creatinine each cycle (with cystatin-C eGFR if it rises)
Serum potassium, magnesium, and total/ionized calcium
ECG/QTc at baseline, ~day 14, and start of cycle 2
LFTs and CBC per label

Key trials & series

MONALEESA-2 / MONALEESA-3 / MONALEESA-7 (OS benefit)
NATALEE (adjuvant)
Avci Ther Adv Med Oncol 2026 nephrotoxicity cohort

Clinical pearls

Ribociclib is the CDK4/6 inhibitor most associated with QT prolongation - check Mg/K/Ca, not just creatinine.
A rising creatinine with a normal cystatin C means keep dosing.
Strong CYP3A4 inhibitors raise both renal-transporter and QT effects by increasing exposure.

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2022–2026 · 4 since 2024

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateRibociclib induced acute kidney injury: A case report.Gulturk I et al. · J Oncol Pharm Pract 2021 · PMID 33847193First reported case of recurrent grade 3 acute kidney injury directly attributable to ribociclib, recurring on rechallenge and forcing permanent discontinuation.CaseC · LimitedRibociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis.Teo SW et al. · BMJ Case Rep 2023 · PMID 37696610Late-onset rhabdomyolysis with subsequent acute kidney injury from a ribociclib-rosuvastatin CYP3A4 interaction occurring years into therapy.CaseC · LimitedLactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.Lagampan C et al. · Cancer Rep (Hoboken) 2022 · PMID 34739192Rising serum creatinine and severe lactic acidosis requiring renal replacement therapy from a ribociclib-metformin transporter interaction in a patient with preexisting renal impairment.

Conference abstracts & journal reports· 1 non-PubMed

Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.

JournalRibociclib-Induced Pseudo-Acute Kidney InjurySy-Go JPT, Yarandi N, Schwartz GL, Herrmann SM · Journal of Onco-Nephrology 2022Isolated serum-creatinine rise on ribociclib with a preserved cystatin-C / measured (iothalamate) GFR, confirming pseudo-AKI from CDK4/6 inhibition of tubular creatinine secretion rather than true injury — the drug was continued. Journal of Onco-Nephrology (not PubMed-indexed).

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Jul 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dose adjustment is necessary in patients with breast cancer who have mild to moderate (30 mL/min to 89 mL/min/1.73 m 2 ≤ estimated glomerular filtration rate (eGFR)) renal impairment. A reduced starting dose of 200 mg is recommended in patients with breast cancer who have severe renal impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)] .

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 31,378 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 5 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Electrolyte Disturbancecorroborated · ROR 2.04 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Electrolyte Disturbance

ROR 2.0495% CI 1.88–2.21· 576 reports

Hypertension

ROR 1.5695% CI 1.46–1.67· 889 reports

Hemorrhagic Cystitis

ROR 1.5495% CI 1.31–1.80· 159 reports

Crystal / Obstructive Nephropathy

ROR 1.4895% CI 1.24–1.76· 123 reports

SIADH / Hyponatremia

ROR 1.4095% CI 1.20–1.63· 168 reports

FAERS outcomes & reporting trend· 14.7% of reports w/ death · 23% w/ hospitalization

14.7%

Reported with a death outcome

4,597 of 31,378 reports

23%

Reported with hospitalization

7,206 of 31,378 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 31,378 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 1.4995% CI 1.34–1.66· 339 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

General / constitutional

Fatigue3,813Pain1,877Asthenia1,612Malaise1,603Pyrexia1,151

Gastrointestinal

Nausea3,805Vomiting2,149Diarrhoea2,069Constipation1,135

Blood & lymphatic

Neutropenia4,093White Blood Cell Count Decreased1,971Anaemia1,511Leukopenia1,454

Skin

Alopecia1,422Pruritus1,365Rash1,300

Respiratory

Dyspnoea1,602Cough1,274

Nervous system

Headache1,347Dizziness1,249

Musculoskeletal

Arthralgia1,405

Metabolic & electrolyte

Decreased Appetite1,405

Cardiac

Electrocardiogram Qt Prolonged1,174

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Ribociclib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Palbociclib

Ibrance · CDK4/6 inhibitor

Profile

Generally renally well tolerated.

PSEUDOPRELYTE

Mild#1 · 100% phenotype match

Alectinib

Alecensa · ALK TKI

Profile

Creatinine rise via reduced tubular secretion.

PSEUDOPRE

Mild#2 · 73% phenotype match

Bosutinib

Bosulif · BCR-ABL TKI

Profile

Reversible eGFR decline.

PSEUDOPRE

Mild#3 · 73% phenotype match

Ceritinib

Zykadia · ALK TKI

Profile

GI-driven prerenal AKI.

PREPSEUDO

Mild#4 · 73% phenotype match

Selumetinib

Koselugo · MEK inhibitor

Profile

Creatinine rise in neurofibromatosis.

PRELYTE

Mild#5 · 73% phenotype match

Abemaciclib

Verzenio · CDK4/6 inhibitor

Profile

Benign creatinine rise via tubular secretion block.

PSEUDOPRE

Mild#6 · 73% phenotype match

Compare Ribociclib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across CDK4/6 inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1PalbociclibPSEUDO — Pseudo-AKIMild
2AbemaciclibPSEUDO — Pseudo-AKIFAERS AKIMild
3Ribociclib· this agentPSEUDO — Pseudo-AKIFAERS AKIMild

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Ribociclib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Ribociclib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Tural, Deniz — their work on Ribociclib, on PubMed (opens in a new tab)2 papers · 14 citesPMID 41496429 (opens PubMed in a new tab)PMID 33847193 (opens PubMed in a new tab)

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 13 clinical records among all 18 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.